BioNTech Escalates Legal Battle Over Next-Generation mRNA Vaccine Technology

BioNTech files new patent lawsuit against Moderna's mNEXSPIKE vaccine, alleging infringement of key mRNA design patent and seeking damages as it pivots to oncology.

In a significant escalation of the ongoing intellectual property dispute within the mRNA vaccine sector, BioNTech has initiated fresh litigation against rival Moderna. The core of the conflict centers on the commercial value of specific mRNA designs in the lucrative respiratory therapeutics market and the protection of proprietary innovations.

The Core of the New Legal Challenge

On February 19, 2026, BioNTech filed a new patent infringement lawsuit in a U.S. federal court located in Delaware. The company alleges that Moderna’s latest COVID-19 vaccine candidate, mNEXSPIKE, utilizes BioNTech's protected mRNA technology without authorization.

The legal action specifically points to infringement of U.S. Patent No. 12,133,899, which was granted to BioNTech in November 2024. According to court documents, this patent covers a streamlined vaccine design methodology. Rather than encoding the entire spike protein, this approach targets specific structural elements, including the receptor-binding domain. BioNTech contends this design can potentially elicit a robust immune response with a lower dosage while simultaneously enhancing stability during transportation and storage.

Strategic Stakes: Revenue and Market Control

The lawsuit underscores the high commercial stakes involved. BioNTech has quantified the potential impact, stating in its filing that the mNEXSPIKE product is projected to account for approximately 55% of Moderna’s COVID-19 vaccine revenue during the 2025–2026 respiratory virus season. Consequently, BioNTech is seeking substantial monetary damages, accusing Moderna of willful infringement of its intellectual property.

This latest case adds another layer to the complex web of patent litigation surrounding pandemic-era vaccines. Since 2022, Moderna, BioNTech, and Pfizer have been entangled in multiple legal proceedings concerning the original Comirnaty and Spikevax formulations. The underlying battle is clear: control over foundational platform technology translates to command over future licensing agreements and royalty streams.

Pivoting to Oncology Amid Legal Defenses

While aggressively defending its infectious disease patents in court, BioNTech is concurrently executing a strategic operational pivot. Company leadership has recently emphasized accelerating late-stage oncology programs and combination therapies as a long-term priority. The firm aims to have 15 Phase 3 trials active across various cancer indications by the end of 2026, targeting lung, breast, gastrointestinal, urogenital, and gynecological cancers.

Before that, BioNTech anticipates seven late-stage data readouts from its pipeline within the current year. A recent milestone saw the U.S. Food and Drug Administration (FDA) grant Fast Track designation to its candidate BNT113 for the treatment of HPV16-positive head and neck cancer.

Financial Resilience Underpins the Transition

This strategic shift is backed by a substantial war chest. As of the end of 2025, BioNTech reported holding €17.2 billion in cash and cash investments. This financial buffer is critical, as management does not forecast any oncology-related revenue for 2026, meaning the pipeline represents a significant near-term cost before it can become commercially viable.

The company is also restructuring for scale, having recently appointed new leadership to oversee human resources and organizational development.

On the markets, BioNTech shares were last quoted at €93.40. Following declines in recent months, the new lawsuit highlights a dual corporate focus: legally safeguarding the valuable mRNA legacy from the pandemic era while financially sustaining the costly development of its oncology future.